GI
DNTH icon

GAMMA Investing’s Dianthus Therapeutics DNTH Stock Holding History

GAMMA Investing’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.6K Buy
304
+46
+18% +$4.02K ﹤0.01% 2618
2026
Q1 		$21.7K Buy
258
+24
+10% +$1.39K ﹤0.01% 2674
2025
Q4 		$9.64K Buy
234
+39
+20% +$1.51K ﹤0.01% 2997
2025
Q3 		$7.67K Buy
195
+69
+55% +$1.76K ﹤0.01% 3001
2025
Q2 		$2.35K Sell
126
-88
-41% -$1.65K ﹤0.01% 3361
2025
Q1 		$3.88K Buy
214
+90
+73% +$1.98K ﹤0.01% 3186
2024
Q4 		$2.7K Buy
124
+118
+1,967% +$3.03K ﹤0.01% 3128
2024
Q3 		$164 Buy
+6
New +$167 ﹤0.01% 3526

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

GAMMA Investing's DNTH Position: Q2 2026 in Review

GAMMA Investing increased its Dianthus Therapeutics (DNTH) stake by 18% in Q2 2026, buying an estimated $4.02K and bringing the position to 304 shares worth $29.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

GAMMA Investing first reported a position in DNTH in Q3 2024 and has held it in 8 quarters since. 12 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • GAMMA Investing held 304 shares of Dianthus Therapeutics worth $29.6K as of Q2 2026.
  • GAMMA Investing bought 46 Dianthus Therapeutics shares in Q2 2026, an estimated $4.02K.
  • Dianthus Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2618 holding.
  • GAMMA Investing first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 12 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.